Phase 2 Lymphoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You must already be enrolled in a related screening study called APEC14B1 and have completed the initial eligibility screening before joining this trial
- The child must be a baby aged 365 days (1 year) or younger at the time of diagnosis, and must have been born after at least 36 weeks of pregnancy
- The child must have been newly diagnosed with a specific type of blood cancer called B-cell acute lymphoblastic leukemia (B-ALL), or a related condition called acute leukemia of ambiguous lineage (ALAL), where at least half of the leukemia cells are of the B-cell type
- The leukemia cells must show a specific marker called CD19 on their surface
- The child's parent or legal guardian must sign a written consent form agreeing to take part
- All required legal and regulatory rules for medical studies must be met
Who may not be able to join:
- Children who have Down Syndrome
- Children whose B-ALL developed as a result of chemotherapy treatment for a previous cancer
- Children who have already received chemotherapy drugs for this or any previous cancer diagnosis — with a few specific exceptions:
- Short courses (3 days or less) of certain steroids (prednisone, prednisolone, or methylprednisolone) given in the 7 days before enrollment are allowed; inhaled or skin-applied steroids do not count
- A steroid called dexamethasone is generally not allowed within 28 days before starting treatment, except for a single dose used around a sedation procedure to protect the airway
- A single dose of certain chemotherapy drugs given directly into the spinal fluid (cytarabine or methotrexate) within 7 days before enrollment is allowed
- Up to 3 days of a drug called hydroxyurea given in the 7 days before enrollment is allowed
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Incidence of dose-limiting toxicities (DLTs) (safety phase); Incidence of DLTs (expansion phase); Minimal residual disease (MRD)-negative remission rate
Can't join this trial?
Data last synced from ClinicalTrials.gov: 5 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.